Scarica l'app Stockscreener
99.12
0.49%
0.48
Dopo l'orario di chiusura:
99.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$98.64
Aprire:
$96.47
Volume 24 ore:
1.33M
Relative Volume:
0.42
Capitalizzazione di mercato:
$19.64B
Reddito:
$742.00K
Utile/perdita netta:
$-1.13B
Rapporto P/E:
-16.75
EPS:
-5.9165
Flusso di cassa netto:
$-913.73M
1 W Prestazione:
+6.34%
1M Prestazione:
-2.46%
6M Prestazione:
+116.89%
1 anno Prestazione:
+186.47%
Intervallo 1D:
$96.47
$101.00
Intervallo di 1 settimana:
$91.52
$101.00
Portata 52W:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
99.12 | 19.64B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Jefferies highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) platform in coverage initiation - MSN
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines begins phase 3 pancreatic cancer trial By Investing.com - Investing.com India
Revolution Medicines, Inc. (RVMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revolution Medicines, Inc. (RVMDW) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines (RVMD) Begins Phase 3 Trial for Pancreatic Cancer Drug - GuruFocus
Wells Fargo Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $144 - Moomoo
Revolution Medicines begins phase 3 pancreatic cancer trial - Investing.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer - The Manila Times
Revolution Medicines Begins Treating Patients in Phase 3 - GlobeNewswire
Tema Etfs LLC Decreases Position in Revolution Medicines, Inc. $RVMD - MarketBeat
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum - finance.yahoo.com
Piper Sandler Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Behavioral Patterns of RVMD and Institutional Flows - Stock Traders Daily
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines' Readout of Trial for Pancreatic Cancer Drug Likely Positive, Oppenheimer Says - MarketScreener
Jefferies Highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) Platform in Coverage Initiation - Insider Monkey
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now? - Insider Monkey
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Revolution Medicines (RVMD) down 8.8% since last earnings report: Can it rebound? - MSN
Revolution Medicines (RVMD) Stock: Executive Sells $3.5M While Wall Street Upgrades to Strong-Buy - mexc.co
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren’t Flinching - mexc.co
Vanguard (RVMD) files amendment showing 0 shares of Revolution Medicines - Stock Titan
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren't Flinching - CoinCentral
Revolution Medicines exec Mancini sells $3.5m in shares - Investing.com
Revolution Medicines exec Mancini sells $3.5m in shares By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) officer exercises options, sells 37,450 shares under 10b5-1 plan - Stock Titan
Anthony Mancini of Revolution Medicines (RVMD) details stock options and RSUs - Stock Titan
Revolution Medicines (RVMD) CDO details initial option and RSU stake - Stock Titan
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
Revolution Medicines (NASDAQ:RVMD) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
MIL:1RVMD PB Ratio: 12.09 — 225% Above Median - GuruFocus
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock - Defense World
Revolution Medicines (NASDAQ:RVMD) CFO Sells $273,868.44 in Stock - Defense World
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Revolution Medicines, Inc.: Fundamental Analysis and Financial Ratings | 1RVMD | US76155X1000 - marketscreener.com
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD) - MarketBeat
Revolution Medicines Insider Sold Shares Worth $455,919, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):